Buys | $324,442 | 3 | 33 |
Sells | $53,578 | 6 | 67 |
Hasnain Faheem | President & CEO | 1 | $250,282 | 1 | $26,773 | $223,509 |
Giraudo Bryan | COO/CFO | 1 | $59,110 | 1 | $7,431 | $51,679 |
Smith Robert Paul JR | Chief Commercial Officer | 1 | $15,050 | 0 | $0 | $15,050 |
Peterson Caryn | EVP, Regulatory Affairs | 0 | $0 | 1 | $5,343 | $-5,343 |
Aranda Richard | Chief Medical Officer | 0 | $0 | 2 | $6,602 | $-6,602 |
Christian Waage | EVP, Tech Ops and Admin | 0 | $0 | 1 | $7,430 | $-7,430 |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel …
Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.
On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $287,158 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $250,282. Giraudo Bryan (COO/CFO) — $59,110. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.
The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.
2024-06-24 | Sale | Aranda Richard | Chief Medical Officer | 1,908 0.0007% | $0.66 | $1,260 | +12.58% | |
2024-06-21 | Hasnain Faheem | President & CEO | 372,000 0.2168% | $0.67 | $250,282 | +43.08% | ||
2024-06-18 | Giraudo Bryan | COO/CFO | 100,000 0.0512% | $0.59 | $59,110 | +71.42% | ||
2024-06-17 | Smith Robert Paul JR | Chief Commercial Officer | 25,000 0.013% | $0.60 | $15,050 | +78.73% | ||
2024-03-27 | Sale | Christian Waage | EVP, Tech Ops and Admin | 6,430 0.0028% | $1.16 | $7,430 | -22.33% | |
2024-03-27 | Sale | Hasnain Faheem | President & CEO | 23,172 0.0101% | $1.16 | $26,773 | -22.33% | |
2024-03-27 | Sale | Giraudo Bryan | COO/CFO | 6,430 0.0028% | $1.16 | $7,431 | -22.33% | |
2024-03-18 | Sale | Aranda Richard | Chief Medical Officer | 4,018 0.0017% | $1.33 | $5,342 | -34.02% | |
2024-03-18 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,018 0.0017% | $1.33 | $5,343 | -34.02% | |
2023-11-15 | Milligan Sandra | director | 32,000 0.0139% | $0.79 | $25,213 | +11.07% | ||
2023-11-13 | Giraudo Bryan | COO/CFO | 200,000 0.0795% | $0.56 | $112,880 | +43.00% | ||
2023-06-22 | Sale | Aranda Richard | Chief Medical Officer | 1,814 0.0018% | $1.29 | $2,340 | -34.61% | |
2023-04-04 | Giraudo Bryan | COO/CFO | 55,000 0.0583% | $1.02 | $56,095 | +3.96% | ||
2023-03-16 | Sale | Aranda Richard | Chief Medical Officer | 7,563 0.0083% | $1.10 | $8,304 | 0.00% | |
2023-03-16 | Sale | Carter Laura | Chief Scientific Officer | 6,029 0.0066% | $1.10 | $6,620 | 0.00% | |
2023-03-16 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 7,564 0.0083% | $1.10 | $8,305 | 0.00% | |
2022-10-24 | Sale | Aranda Richard | Chief Medical Officer | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
2022-10-24 | Sale | Carter Laura | Chief Scientific Officer | 4,876 0.0058% | $12.07 | $58,868 | -88.98% | |
2022-10-24 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
2022-07-15 | Hasnain Faheem | President & CEO | 138,696 0.099% | $7.21 | $999,998 | -79.92% |
Hasnain Faheem | President & CEO | 5408073 2.3866% | $7.84M | 4 | 2 | <0.0001% |
Christian Waage | EVP, Tech Ops and Admin | 585934 0.2586% | $849,604.30 | 4 | 3 | <0.0001% |
Giraudo Bryan | COO/CFO | 480010 0.2118% | $696,014.50 | 9 | 3 | +0.58% |
Smith Robert Paul JR | Chief Commercial Officer | 25000 0.011% | $36,250.00 | 1 | 0 | |
Gujrathi Sheila | President & CEO | 4048242 1.7865% | $5.87M | 1 | 0 | <0.0001% |
$99,438,720 | 81 | 6.74% | $290.44M | |
$5,911,307 | 70 | -1.38% | $309.77M | |
$109,415,500 | 33 | 18.13% | $353.41M | |
$41,446,394 | 27 | 12.91% | $340.18M | |
$24,857,912 | 21 | -35.40% | $287.11M |
Increased Positions | 49 | +44.95% | 23M | +13.38% |
Decreased Positions | 40 | -36.7% | 27M | -15.41% |
New Positions | 18 | New | 2M | New |
Sold Out Positions | 13 | Sold Out | 6M | Sold Out |
Total Postitions | 118 | +8.26% | 171M | -2.02% |
Octagon Capital Advisors Lp | $22,571.00 | 8.08% | 18.35M | +9M | +99.72% | 2024-12-31 |
Nea Management Company, Llc | $22,254.00 | 7.97% | 18.09M | 0 | 0% | 2024-12-31 |
Vanguard Group Inc | $12,342.00 | 4.42% | 10.03M | -2M | -14.63% | 2024-12-31 |
Alyeska Investment Group, L.P. | $10,834.00 | 3.88% | 8.81M | +3M | +52.73% | 2024-12-31 |
Arch Venture Management, Llc | $9,909.00 | 3.55% | 8.06M | 0 | 0% | 2024-12-31 |
Fmr Llc | $9,758.00 | 3.5% | 7.93M | -2,735 | -0.03% | 2024-12-31 |
683 Capital Management, Llc | $8,579.00 | 3.07% | 6.97M | +1M | +20.26% | 2024-12-31 |
Palo Alto Investors Lp | $7,721.00 | 2.77% | 6.28M | 0 | 0% | 2024-12-31 |
Silverarc Capital Management, Llc | $7,591.00 | 2.72% | 6.17M | +526,495 | +9.33% | 2024-12-31 |
Samsara Biocapital, Llc | $7,540.00 | 2.7% | 6.13M | 0 | 0% | 2024-12-31 |